Search

Displaying results 1061 - 1070 of 2872 in total
  1. Drug

    PF-03654746

    go.drugbank.com/drugs/DB12201
    Investigational

    PF-03654746 has been investigated for the treatment of Narcolepsy, Schizophrenia, Tourette's Syndrome, and Excessive Daytime Sleepiness.

  2. Drug

    Ebvaciclib

    go.drugbank.com/drugs/DB18967
    Investigational

    Ebvaciclib is under investigation in clinical trial NCT03519178 (A Study of PF-06873600 in People With Cancer).

  3. Drug

    Mosliciguat

    go.drugbank.com/drugs/DB19425
    Investigational

    Mosliciguat is under investigation in clinical trial NCT06635850 (A Phase 2 Study of Mosliciguat in PH-ILD).

  4. Drug

    NOV-002

    go.drugbank.com/drugs/DB05393
    Investigational

    It has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.

  5. Drug

    Zinc gluconate

    go.drugbank.com/drugs/DB11248
    ApprovedInvestigationalVet approved

    It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and with decreased symptom severity.

  6. Drug

    Mycophenolate mofetil

    go.drugbank.com/drugs/DB00688
    ApprovedInvestigational

    A180799,A180805] Previously, mycophenolic acid (MPA) was administered to individuals with autoimmune diseases beginning in the 1970s, but was discontinued due to gastrointestinal effects and concerns over

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  7. Drug

    Tetryzoline

    go.drugbank.com/drugs/DB06764
    Approved

    Tetryzoline is found in a wide array of over-the-counter eye drops, including the most common brand, Visine.

  8. Drug

    Plazomicin

    go.drugbank.com/drugs/DB12615
    Approved

    However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations [A33942

  9. Drug

    Vedolizumab

    go.drugbank.com/drugs/DB09033
    ApprovedInvestigational

    [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.

  10. Drug

    Silodosin

    go.drugbank.com/drugs/DB06207
    ApprovedInvestigational

    [L32368] Most commonly affecting males over the age of 40 years, benign prostatic hyperplasia is the non-malignant enlargement of the prostate gland, associated with lower urinary tract symptoms that have

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates